Open AccessOlmesartan-induced enteropathy
Author(s) -
Nirmal Onteddu,
Venkata Siva Krishna Kumar Pulivarthi,
Mihira Ginnavaram,
Ramalinga Kedika
Publication year - 2018
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2018-224411
Subject(s) - medicine , olmesartan , enteropathy , vomiting , adverse effect , weight loss , nausea , villous atrophy , sprue , pediatrics , diarrhea , intensive care medicine , disease , coeliac disease , mold , biology , blood pressure , genetics , obesity
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. We describe a 68-year-old Caucasian woman with a history of hypothyroidism and hypertension who presented to our hospital with recurrent episodes of acute intermittent diarrhoea, nausea, vomiting, renal failure and 15 lbs weight loss. After an extensive workup, she was diagnosed with possible OIE. Cessation of the offending drug resulted in improvement of clinical symptoms and also hospital admissions for severe diarrhoea reinforcing the diagnosis of OIE. Among the adverse effects of drug therapy, diarrhoea is a relatively frequent adverse event accounting for about 7%. This report serves as an addition to existing literature and to increase the awareness of olmesartan-induced sprue-like enteropathy among the primary care physicians and gastroenterologists.